Patient Square Capital LP Has $3.70 Million Stock Position in Allogene Therapeutics, Inc. $ALLO

Patient Square Capital LP increased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 13.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,981,396 shares of the company’s stock after purchasing an additional 346,396 shares during the quarter. Allogene Therapeutics makes up 1.0% of Patient Square Capital LP’s portfolio, making the stock its 20th largest holding. Patient Square Capital LP owned approximately 1.33% of Allogene Therapeutics worth $3,697,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALLO. Quadrature Capital Ltd raised its holdings in shares of Allogene Therapeutics by 29.6% in the 2nd quarter. Quadrature Capital Ltd now owns 44,050 shares of the company’s stock worth $50,000 after buying an additional 10,059 shares in the last quarter. Brighton Jones LLC lifted its holdings in Allogene Therapeutics by 81.6% during the 3rd quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock valued at $31,000 after purchasing an additional 11,311 shares during the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in Allogene Therapeutics by 19.6% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 85,720 shares of the company’s stock valued at $106,000 after buying an additional 14,032 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in Allogene Therapeutics by 142.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock worth $35,000 after buying an additional 18,314 shares during the last quarter. Finally, Cerity Partners LLC increased its holdings in shares of Allogene Therapeutics by 5.2% during the second quarter. Cerity Partners LLC now owns 400,267 shares of the company’s stock worth $452,000 after buying an additional 19,843 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

NASDAQ ALLO opened at $2.05 on Monday. The stock has a fifty day moving average of $1.61 and a 200-day moving average of $1.36. The stock has a market capitalization of $460.70 million, a P/E ratio of -2.09 and a beta of 0.60. Allogene Therapeutics, Inc. has a 52 week low of $0.86 and a 52 week high of $2.39.

Wall Street Analyst Weigh In

ALLO has been the topic of several recent analyst reports. Citigroup raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, January 9th. Wall Street Zen raised Allogene Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. UBS Group started coverage on Allogene Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Friday, January 9th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.40.

Insider Transactions at Allogene Therapeutics

In related news, SVP Earl Martin Douglas sold 22,900 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $1.76, for a total transaction of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares of the company’s stock, valued at $994,308.48. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Zachary Roberts sold 35,700 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $1.77, for a total transaction of $63,189.00. Following the completion of the transaction, the executive vice president owned 581,166 shares in the company, valued at $1,028,663.82. This represents a 5.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 215,855 shares of company stock valued at $378,426. 13.20% of the stock is owned by company insiders.

Allogene Therapeutics Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.